Legal & General Group Plc increased its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 2.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 112,970 shares of the company's stock after purchasing an additional 2,698 shares during the period. Legal & General Group Plc owned approximately 0.19% of argenx worth $69,477,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC purchased a new position in shares of argenx during the fourth quarter worth $37,000. Global Retirement Partners LLC lifted its stake in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after acquiring an additional 61 shares during the period. Whittier Trust Co. of Nevada Inc. grew its position in argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after acquiring an additional 33 shares in the last quarter. Finally, Huntington National Bank increased its stake in argenx by 1,133.3% during the fourth quarter. Huntington National Bank now owns 74 shares of the company's stock worth $46,000 after purchasing an additional 68 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.
argenx Price Performance
Shares of ARGX traded down $1.01 during midday trading on Tuesday, reaching $605.38. 415,834 shares of the stock were exchanged, compared to its average volume of 308,592. The company has a market capitalization of $36.78 billion, a price-to-earnings ratio of -687.93 and a beta of 0.60. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21. The business's 50-day moving average price is $605.51 and its 200 day moving average price is $604.95.
argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million. As a group, equities research analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.
Analyst Ratings Changes
ARGX has been the subject of several recent research reports. Guggenheim raised their price objective on shares of argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th. William Blair reiterated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Robert W. Baird lifted their target price on argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a report on Tuesday, March 4th. Finally, HC Wainwright restated a "buy" rating and set a $720.00 price target on shares of argenx in a report on Tuesday, April 8th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $690.33.
Read Our Latest Research Report on ARGX
About argenx
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Further Reading
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
